Uveal Melanoma Market, By Diagnosis (Ultrasonography, Indocyanine green angiography, High resolution ultrasound Bio microscopy and Others), By Therapy (Radiation therapy, Surgical resection techniques, Transpupillary thermotherapy and Others), By End-User (Hospital, Ambulatory surgical centres, Ophthalmology clinics and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2034

Uveal Melanoma Market was valued at US$ 1.5 billion in 2024 and is projected to grow at a CAGR of 5.9% to reach US$ 2.5 billion by 2034.

The uveal consists of three sections: the iris, ciliary body, and choroid, which are located in the back of the sclera and the cornea. The iris choroid and cilira body are included in uveal melanoma, which is referred to as skin cancer. This is the stage at which tumors form inside the uva from the melanocytes that give the eye its colour. Although it is a rare disorder, it is the most common form of intraocular malignancy in adults. The size of the tumor is the most important determinant in determining how to treat uveal melanoma. This type of melanoma is essentially asymptomatic in its early stages. Pupil distortion reduced visibility due to hazy vision, and secondary retinal detachment are some of the changes that can be seen in tumor enlargement over time. This type of cancer is associated with fair hair, green or light coloured eyes, and an advanced age. The function of inherited genetic alterations in uveal melanoma is unknown.

Impact of Covid-19 pandemic on market

The COVID-19 epidemic has a significant influence on the industry because the virus dwells in the back of the nose, there was a high risk of transfer, which concerned uveal melanoma therapy surgeons in particular. Surgeons communicate with their patients using telemedicine. Only emergency surgeries are available, with severe procedures to follow. A breakthrough now could limit the revenue of uveal melanoma therapy product producers, putting the uveal melanoma treatment market at risk.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Opportunities for Uveal Melanoma Treatment Manufacturers

The creation of a reliable uveal melanoma screening method will help to reduce mortality by detecting the disease early. Recognition and screening for uveal melanoma have improved in recent decades, allowing for early discovery of the disease. However, the ultimate goal of lowering the rate of late-stage sickness and mortality has not been met. This is due to insufficient screening processes, which result in both false-positive and false-negative results. Companion diagnostic tests that achieve these requirements will gain rapid popularity among doctors and patient populations. In the near future, rising demand for safe non-invasive screening technologies is projected to boost the expansion of the uveal melanoma therapy market.

Growth in business operations by emerging and small sized players

The rise in the number of incidences of eye cancer is driving the global market for uveal melanoma treatment. The surge in the usage of electronic gadgets is thought to be one of the major causes of the increase. This could be related to the dangerous UV radiation that users of smartphones, tablets, desktops, laptops, and other electronic gadgets are exposed to. Adults aged 60 and above spend 5 or more hours each day on digital devices, according to the American Cancer Society, and prefer laptops and desktops for internet browsing. As a result, the market for uveal melanoma treatment is predicted to develop.

The Uveal Melanoma market is segmented based on diagnosis, therapy, end-user, and region.

On the basis of Diagnosis, the uveal melanoma market is segmented into Ultrasonography, Indocyanine green angiography, High resolution ultrasound Biomicroscopy and Others. Based on Therapy, the target market is segmented into Radiation therapy, Surgical resection techniques, Transpupillary thermotherapy and Others. On the basis of End-User, the target market is segmented into Hospital, Ambulatory surgical centers, Ophthalmology clinics and Others.

Regional Insights:

On region the Uveal Melanoma market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds the largest market share of uveal melanoma treatment market. One of the main causes is the availability of improved healthcare services and facilities, which enable early detection of uveal melanoma and a variety of palliative treatments.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the uveal melanoma market report based on diagnosis, treatment, end-user, and region.

Uveal Melanoma Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the uveal melanoma market includes Eli Lilly &Co., Novartis AG, Bayer, AstraZeneca, Amgen, Pfizer Inc., Roche, Spectrum pharmaceuticals and Others.  Many companies in the uveal melanoma treatment industry are attempting to expand their product offerings. However, the most effective way to increase the number of customers is to market the goods through internet portals.

Recent Developments:

• In 2021 Novartis declared that their experimental drug's phase 3 clinical study would begin. TNO155 is being used to treat uveal melanoma. Targeting a particular protein, TNO155 is a targeted therapy that prevents the proliferation of cancer cells.

• Pfizer, Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Eli Lilly &Co.
• Novartis AG
• Bayer
• Eli Lilly &Co.
• AstraZeneca
• Amgen
• Roche
• Spectrum pharmaceuticals
• Others

 “*” marked represents similar segmentation in other categories in the respective section.